The USPTO issued Patent No. US12594263B2 to Nurix Therapeutics, Inc. for methods and compositions using novel CBL (Casitas B-lineage lymphoma) inhibitors to enhance expansion of immune cells for cell-based immunotherapeutics. The patent includes 31 claims covering pharmaceutical compositions, methods of treatment, and cell preparations. Filing date was September 23, 2020, under Application No. 17030258.

Pharmaceutical and biotechnology companies developing cell-based immunotherapies, CAR-T technologies, or related immune cell expansion methods should review this patent to assess freedom-to-operate considerations. Patent holders should ensure proper marking and consider enforcement timelines. This grant does not impose compliance obligations but establishes enforceable intellectual property rights in the biotechnology sector.